Related Experiment Video
Updated: Jul 8, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Imatinib mesylate in chronic myeloid leukemia
Angelo Michele Carella1, Enrica Lerma
1Division of Hematology I and Stem Cell Transplantation Unit, Azienda Ospedaliera Universitaria San Martino, Genoa, Italy. angelomichele.carella@hsanmartino.it
Current Stem Cell Research & Therapy
|January 29, 2008
Summary
Imatinib mesylate is a recommended standard treatment for chronic myeloid leukemia (CML). This review covers its effective management, monitoring, and updated clinical trial results for CML patients.
Area of Science:
- Onco-hematology
- Molecular targeted therapy
Background:
- Chronic myeloid leukemia (CML) management has been revolutionized by targeted therapies.
- The p210Bcr-Abl oncoprotein's tyrosine kinase activity is a key driver of CML.
- Imatinib mesylate, a pioneering tyrosine kinase inhibitor (TKI), demonstrated efficacy and safety in CML treatment.
Purpose of the Study:
- To review current strategies for effective CML management using Imatinib.
- To provide updated results from the IRIS and RIGHT clinical trials.
- To offer recommendations for monitoring patients treated with Imatinib.
Main Methods:
- Review of existing literature and clinical trial data.
- Analysis of five-year experience with Imatinib mesylate.
- Discussion of monitoring tools and strategies for Imatinib-treated patients.
Main Results:
- Imatinib mesylate (400 mg daily) is recommended as the gold standard for newly diagnosed CML.
- Updated IRIS and RIGHT trial results support the long-term efficacy and safety of Imatinib.
- Effective management requires continuous monitoring of Imatinib-treated patients.
Conclusions:
- Imatinib mesylate remains a cornerstone therapy for chronic myeloid leukemia.
- Adherence to recommended dosage and vigilant patient monitoring are crucial for optimal outcomes.
- Ongoing research and clinical trials continue to refine CML treatment paradigms.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...